Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors : Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU
Copyright © 2023 The Author(s). Publicado por Elsevier España, S.L.U. All rights reserved..
The development of the immune checkpoint inhibitors (ICI) is one of the most remarkable achievements in cancer therapy in recent years. However, their exponential use has led to an increase in immune-related adverse events (irAEs). Gastrointestinal and liver events encompass hepatitis, colitis and upper digestive tract symptoms accounting for the most common irAEs, with incidence rates varying from 2% to 40%, the latter in patients undergoing combined ICIs therapy. Based on the current scientific evidence derived from both randomized clinical trials and real-world studies, this statement document provides recommendations on the diagnosis, treatment and prognosis of the gastrointestinal and hepatic ICI-induced adverse events.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Gastroenterologia y hepatologia - 47(2024), 4 vom: 20. März, Seite 401-432 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Riveiro-Barciela, Mar [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.03.2024 Date Revised 26.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.gastrohep.2023.10.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367190117 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367190117 | ||
| 003 | DE-627 | ||
| 005 | 20240326235240.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240117s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.gastrohep.2023.10.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1348.xml |
| 035 | |a (DE-627)NLM367190117 | ||
| 035 | |a (NLM)38228461 | ||
| 035 | |a (PII)S0210-5705(23)00455-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Riveiro-Barciela, Mar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors |b Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2024 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Publicado por Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a The development of the immune checkpoint inhibitors (ICI) is one of the most remarkable achievements in cancer therapy in recent years. However, their exponential use has led to an increase in immune-related adverse events (irAEs). Gastrointestinal and liver events encompass hepatitis, colitis and upper digestive tract symptoms accounting for the most common irAEs, with incidence rates varying from 2% to 40%, the latter in patients undergoing combined ICIs therapy. Based on the current scientific evidence derived from both randomized clinical trials and real-world studies, this statement document provides recommendations on the diagnosis, treatment and prognosis of the gastrointestinal and hepatic ICI-induced adverse events | ||
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Colitis | |
| 650 | 4 | |a Diarrea | |
| 650 | 4 | |a Diarrhea | |
| 650 | 4 | |a Drug-induced liver injury | |
| 650 | 4 | |a Efectos adversos inmunomediados | |
| 650 | 4 | |a Hepatitis | |
| 650 | 4 | |a Hepatotoxicidad | |
| 650 | 4 | |a Immune checkpoint inhibitors | |
| 650 | 4 | |a Immune-related adverse events | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Inhibidores de checkpoint inmunológicos | |
| 650 | 4 | |a Inmunoterapia | |
| 650 | 4 | |a Toxicidad | |
| 650 | 4 | |a Toxicity | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 700 | 1 | |a Carballal, Sabela |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz-González, Álvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Mañosa, Míriam |e verfasserin |4 aut | |
| 700 | 1 | |a Gallego-Plazas, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Cubiella, Joaquín |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez-Fonseca, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Varela, María |e verfasserin |4 aut | |
| 700 | 1 | |a Menchén, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Sangro, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Montes, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Mesonero, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Gandía, Miguel Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Rivera, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Londoño, María-Carlota |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastroenterologia y hepatologia |d 1993 |g 47(2024), 4 vom: 20. März, Seite 401-432 |w (DE-627)NLM075187280 |x 0210-5705 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2024 |g number:4 |g day:20 |g month:03 |g pages:401-432 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.gastrohep.2023.10.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2024 |e 4 |b 20 |c 03 |h 401-432 | ||